Endocrinology and Metabolism

Sung-Koo Kang (Kang SK)

3 Articles

Clinical Study
Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease: Dug-Hyun Choi, Chan-Hee Jung, Ji-Oh Mok, Chul-Hee Kim, Sung-Koo Kang, Bo-Yeon Kim; Endocrinol Metab. 2018;33(3):387-394. Published online September 18, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.3.387

6,623 View
128 Download
40 Web of Science
40 Crossref

Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are expected to improve the liver function of patients with non-alcoholic fatty liver disease (NAFLD) combined type 2 diabetes mellitus (T2DM) by its characteristic mechanism. This study was designed to investigate the effect of dapagliflozin, one of the SGLT2i, on the liver function of T2DM with NAFLD when combined with metformin.

Methods

Among patients who received dual oral hypoglycemic agents within the 3 months of diagnosing NAFLD, patients who had abnormal alanine aminotransferase (ALT) level (>40 IU/L) were included. Patients were divided into two groups: metformin+dapagliflozin group and metformin+dipeptidyl peptidase-4 inhibitors (DPP4i) group. Demographic data, biochemical data and the clinical and treatment histories of all patients were reviewed.

Results

A total of 102 patients were included (dapagliflozin group, n=50; DPP4i group, n=52). Dapagliflozin group showed more weight loss and more ALT decline than DPP4i group (−2.9 kg vs. −0.4 kg, P=0.005; −21.1 U/L vs. −9.5 U/L, P=0.008, respectively) and the proportion of patients with ALT normalization after treatment was also significantly higher in the dapagliflozin group (80.0% vs. 61.5%, P=0.041). The effect of dapagliflozin with metformin on ALT normalization remained significant after adjustment for confounding variables including body weight loss (odds ratio, 3.489; P=0.046).

Conclusion

ALT improvement was statistically significant in the dapagliflozin than the DPP4i when combined with metformin and the result was consistent after adjustment for confounding variables including body weight loss.

Citations

Citations to this article as recorded by

Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study
Vicente Pallarés-Carratalá, Antonio Ruiz-García, Adalberto Serrano-Cumplido, Antonio Segura Fragoso, Verónica Fernández-Pascual, Beatriz Sánchez-Sánchez, María Inmaculada Cervera-Pérez, Francisco Javier Alonso-Moreno, Ezequiel Arranz-Martínez, Alfonso Bar
Clínica e Investigación en Arteriosclerosis.2025; 37(1): 100724. CrossRef
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari,
Journal of Clinical Medicine.2025; 14(2): 428. CrossRef
Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study
Vicente Pallarés-Carratalá, Antonio Ruiz-García, Adalberto Serrano-Cumplido, Antonio Segura Fragoso, Verónica Fernández-Pascual, Beatriz Sánchez-Sánchez, María Inmaculada Cervera-Pérez, Francisco Javier Alonso-Moreno, Ezequiel Arranz-Martínez, Alfonso Bar
Clínica e Investigación en Arteriosclerosis (English Edition).2025; 37(1): 100724. CrossRef
Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis
Xingyu Fan, Yueyue Wang, Yue Wang, Hao Duan, Yijun Du, Tianrong Pan, Xing Zhong
BMC Pharmacology and Toxicology.2025;[Epub] CrossRef
Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials
Samuel Dinerman, Yan Shu
International Journal of Translational Medicine.2025; 5(1): 7. CrossRef
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Maria Zachou, Pagona Flevari, Narjes Nasiri-Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva Kassi, Theodoros Androutsakos
European Journal of Clinical Pharmacology.2024; 80(1): 127. CrossRef
Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis
Hirokazu Takahashi, Keiko Asakawa, Yoshinori Kosakai, Takumi Lee, Mitsuhiro Rokuda
Diabetes, Obesity and Metabolism.2024; 26(3): 997. CrossRef
Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes
Xiuying Gao, Chuanming Zhu, Wei Zhu, Lin Wang
Biomedical Reports.2024;[Epub] CrossRef
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, Erica Vetrano, Giulia Medicamento, Carlo Acierno, Luca Rinaldi, Aldo Marrone, Teresa Salvatore, Marcellino Monda, Celestino Sardu, Raffaele Marfella, Ferdinando Carlo Sasso
Biomedicines.2023; 11(2): 322. CrossRef
Swimming exercise ameliorates insulin resistance and nonalcoholic fatty liver by negatively regulating PPARγ transcriptional network in mice fed high fat diet
Yong Zhang, Jie Xu, Di Zhou, Tingting Ye, Puqing Zhou, Zuofeng Liu, Xinyuan Liu, Zinan Wang, Tianmiao Hua, Zhenghao Zhang, Qingyan Sun
Molecular Medicine.2023;[Epub] CrossRef
Association between Obstructive Sleep Apnea and Heart Failure in Adults—A Systematic Review
Agnieszka Polecka, Natalia Olszewska, Łukasz Danielski, Ewa Olszewska
Journal of Clinical Medicine.2023; 12(19): 6139. CrossRef
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome.2023; (5): 8. CrossRef
Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
Mazhar Hussain, Muhammad Zafar Majeed Babar, Saba Tariq, Muhammad Irfan Ahmad, Lubna Akhtar
International Journal of Diabetes in Developing Countries.2022; 42(2): 290. CrossRef
The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis
Manqiu Mo, Zichun Huang, Yuzhen Liang, Yunhua Liao, Ning Xia
Digestive and Liver Disease.2022; 54(4): 461. CrossRef
Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation
Reem M. Hazem, Ahmed Z. Ibrahim, Dina A. Ali, Yasser M. Moustafa
International Immunopharmacology.2022; 104: 108503. CrossRef
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Theodoros Androutsakos, Narjes Nasiri-Ansari, Athanasios-Dimitrios Bakasis, Ioannis Kyrou, Efstathios Efstathopoulos, Harpal S. Randeva, Eva Kassi
International Journal of Molecular Sciences.2022; 23(6): 3107. CrossRef
Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
Panshuang Qiao, Yingli Jia, Ang Ma, Jinzhao He, Chen Shao, Xiaowei Li, Shuyuan Wang, Baoxue Yang, Hong Zhou
Frontiers in Pharmacology.2022;[Epub] CrossRef
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial
Yumie Takeshita, Masao Honda, Kenichi Harada, Yuki Kita, Noboru Takata, Hiromasa Tsujiguchi, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Eishiro Mizukoshi, Hiroyuki Nakamura, Shuichi Kaneko, Toshinari Takamura
Diabetes Care.2022; 45(9): 2064. CrossRef
Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes
Vincenzo Maria Monda, Sandro Gentile, Francesca Porcellati, Ersilia Satta, Alessandro Fucili, Marcello Monesi, Felice Strollo
Advances in Therapy.2022; 39(11): 4837. CrossRef
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms
Hager H. Shaaban, Ibrahim Alzaim, Ahmed El-Mallah, Rania G. Aly, Ahmed F. El-Yazbi, Ahmed Wahid
Life Sciences.2022; 308: 120956. CrossRef
The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
Lampros Chrysavgis, Alkistis‐Maria Papatheodoridi, Antonios Chatzigeorgiou, Evangelos Cholongitas
Journal of Gastroenterology and Hepatology.2021; 36(4): 893. CrossRef
Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
Chloe Wong, Clyve Yu Leon Yaow, Cheng Han Ng, Yip Han Chin, Yi Fen Low, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Chin Meng Khoo
Frontiers in Endocrinology.2021;[Epub] CrossRef
Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
Francisca dos Santos Coelho, Marta Borges‐Canha, Madalena von Hafe, João Sérgio Neves, Catarina Vale, Ana Rita Leite, Davide Carvalho, Adelino Leite‐Moreira
Diabetes/Metabolism Research and Reviews.2021;[Epub] CrossRef
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Elizabeth M. Lamos, Megan Kristan, Maka Siamashvili, Stephen N. Davis
Expert Review of Clinical Pharmacology.2021; 14(7): 837. CrossRef
Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Won Euh, Soo Lim, Jin-Wook Kim
Frontiers in Endocrinology.2021;[Epub] CrossRef
Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway
Jingyi Luo, Pengbo Sun, Yangyang Wang, Yang Chen, Yaoyun Niu, Yipei Ding, Naihan Xu, Yaou Zhang, Weidong Xie
European Journal of Pharmacology.2021; 907: 174304. CrossRef
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease
Susrichit Phrueksotsai, Kanokwan Pinyopornpanish, Juntima Euathrongchit, Apinya Leerapun, Arintaya Phrommintikul, Supawan Buranapin, Nipon Chattipakorn, Satawat Thongsawat
Journal of Gastroenterology and Hepatology.2021; 36(10): 2952. CrossRef
Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
Vincenzo Maria Monda, Francesca Porcellati, Felice Strollo, Alessandro Fucili, Marcello Monesi, Ersilia Satta, Sandro Gentile
Advances in Therapy.2021; 38(8): 4195. CrossRef
Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B
Lilian Yan Liang, Vincent Wai‐Sun Wong, Vicki Wing‐Ki Hui, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Grace Chung‐Yan Lui, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong
GastroHep.2021; 3(4): 261. CrossRef
Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels
Kanokwan Pinyopornpanish, Apinya Leerapun, Kanokporn Pinyopornpanish, Nipon Chattipakorn
Gut and Liver.2021; 15(6): 827. CrossRef
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
F. Anthony Romero, Christopher T. Jones, Yingzi Xu, Martijn Fenaux, Randall L. Halcomb
Journal of Medicinal Chemistry.2020; 63(10): 5031. CrossRef
SGLT2 Inhibitors in Liver Patients
John Chen Hsiang, Vincent Wai-Sun Wong
Clinical Gastroenterology and Hepatology.2020; 18(10): 2168. CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430. CrossRef
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
Metabolism.2019; 92: 82. CrossRef
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, Cheol-Young Park
Diabetes & Metabolism Journal.2019; 43(2): 127. CrossRef
Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet
Fan Zheng, Ying Cai
Lipids in Health and Disease.2019;[Epub] CrossRef
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Chan-Hee Jung, Ji-Oh Mok
Journal of Obesity & Metabolic Syndrome.2019; 28(1): 18. CrossRef
Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
Niki Katsiki, Nikolaos Perakakis, Christos Mantzoros
Metabolism.2019; 98: iii. CrossRef
Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
Molecular and Cellular Endocrinology.2019; 498: 110539. CrossRef
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
A.J. Scheen
Diabetes & Metabolism.2019; 45(3): 213. CrossRef

Obesity and Metabolism
Serum Concentrations of Ghrelin and Leptin according to Thyroid Hormone Condition, and Their Correlations with Insulin Resistance: Kyu-Jin Kim, Bo-Yeon Kim, Ji-Oh Mok, Chul-Hee Kim, Sung-Koo Kang, Chan-Hee Jung; Endocrinol Metab. 2015;30(3):318-325. Published online May 18, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.3.318

5,480 View
50 Download
11 Web of Science
13 Crossref

Abstract PDF PubReader

Background

Thyroid hormones can influence energy metabolism and insulin sensitivity via their interaction with adipocytokines and gut hormones. The aims of this study were to evaluate differences in serum ghrelin and leptin concentrations according to thyroid hormone levels, and to investigate the correlation of insulin resistance.

Methods

A total of 154 patients (57 hyperthyroid patients, 61 euthyroid patients, and 36 hypothyroid patients; mean age, 47.9 years) were enrolled. Serum leptin, ghrelin, and insulin levels were measured and insulin resistance was calculated using the formula of the homeostasis model assessment of insulin resistance (HOMA-IR).

Results

There were no differences in mean concentrations of ghrelin or leptin among the three groups. There were no significant differences in insulin levels between the groups (P=0.06), although hyperthyroid patients had borderline statistically significantly higher levels of insulin than did euthyroid subjects by post hoc test (26.4 µIU/mL vs. 16.1 µIU/mL, P=0.057). Regarding HOMA-IR index, the mean levels were highest in the hyperthyroid group among those of the three groups (hyperthyroid vs. euthyroid vs. hypothyroid, 6.7 vs. 3.8 vs. 4.4, P=0.068). Plasma levels of ghrelin were significantly negatively correlated with age, insulin, glucose, body mass index (BMI), and HOMA-IR. Plasma levels of leptin showed significant positive correlation with BMI and triglyceride. There were no significant correlations among thyroid hormone, thyrotropin, ghrelin, leptin, or insulin.

Conclusion

The present study found that serum ghrelin, leptin, and insulin levels didn't differ according to thyroid function conditions. Further studies with larger numbers of patients are required to establish a direct relationship between plasma ghrelin, leptin, and thyroid hormone.

Citations

Citations to this article as recorded by

Relationship between ghrelin and thyroid disease: a meta-analysis
Caihong Xin, Jiayi Yao, Huijuan Li, Xin Sun, Huijuan Wang
Frontiers in Endocrinology.2025;[Epub] CrossRef
Thyroid disorders and gastrointestinal dysmotility: an old association
Guang-Meng Xu, Ming-Xin Hu, Si-Yu Li, Xuan Ran, Hao Zhang, Xiang-Fu Ding
Frontiers in Physiology.2024;[Epub] CrossRef
Insulin resistance, leptin and adiponectin in lean and hypothyroid children and adolescents with obesity
Doaa El Amrousy, Dalia El-Afify, Shaimaa Salah
BMC Pediatrics.2022;[Epub] CrossRef
Mediators of energy homeostasis in hyperthyroidism
Avinash Patil, Suresh Vaikkakara, Mani Deepthi Dasari, Sandeep Ganta, Alok Sachan, Kiranmayi S. Vinapamula
Archives of Endocrinology and Metabolism.2022;[Epub] CrossRef
STUDY OF GHRELIN LEVELS IN HYPOTHYROID PATIENTS BEFORE AND AFTER TREATMENT
Peeyush Yadav, G. G. Kaushik
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 52. CrossRef
Acylated Ghrelin Attenuates l-Thyroxin–induced Cardiac Damage in Rats by Antioxidant and Anti-inflammatory Effects and Downregulating Components of the Cardiac Renin–angiotensin System
Rehab Badi
Journal of Cardiovascular Pharmacology.2021; 78(3): 422. CrossRef
Experimental hypothyroidism in adult male rats: the effects of Artemisia dracunculus aqueous extract on serum thyroid hormones, lipid profile, leptin, adiponectin, and antioxidant factors
Mohammad Mohsen Mohammadi, Mahdi Saeb, Saeed Nazifi
Comparative Clinical Pathology.2020; 29(2): 485. CrossRef
Leptin, neuropeptide Y (NPY), melatonin and zinc levels in experimental hypothyroidism and hyperthyroidism: relation with melatonin and the pineal gland
Abdulkerim Kasım Baltaci, Rasim Mogulkoc
Hormone Molecular Biology and Clinical Investigation.2018;[Epub] CrossRef
Leptin, NPY, Melatonin and Zinc Levels in Experimental Hypothyroidism and Hyperthyroidism: The Relation to Zinc
Abdulkerim Kasım Baltaci, Rasim Mogulkoc
Biochemical Genetics.2017; 55(3): 223. CrossRef
Thyroid Hormone Regulation and Insulin Resistance: Insights From Animals Naturally Adapted to Fasting
Bridget Martinez, Rudy M. Ortiz
Physiology.2017; 32(2): 141. CrossRef
Role of the Orexin System on the Hypothalamus-Pituitary-Thyroid Axis
Antonietta Messina, Carolina De Fusco, Vincenzo Monda, Maria Esposito, Fiorenzo Moscatelli, Anna Valenzano, Marco Carotenuto, Emanuela Viggiano, Sergio Chieffi, Vincenzo De Luca, Giuseppe Cibelli, Marcellino Monda, Giovanni Messina
Frontiers in Neural Circuits.2016;[Epub] CrossRef
Serum Concentrations of Ghrelin and Leptin according to Thyroid Hormone Condition, and Their Correlations with Insulin Resistance (Endocrinol Metab2015;30:318-25, Kyu-Jin Kim et al.)
Jin Hwa Kim
Endocrinology and Metabolism.2015; 30(4): 631. CrossRef
Serum Concentrations of Ghrelin and Leptin according to Thyroid Hormone Condition, and Their Correlations with Insulin Resistance (Endocrinol Metab2015;30:318-25, Kyu-Jin Kim et al.)
Chan-Hee Jung
Endocrinology and Metabolism.2015; 30(4): 633. CrossRef

Obesity and Metabolism
Association between Cardiac Autonomic Neuropathy, Diabetic Retinopathy and Carotid Atherosclerosis in Patients with Type 2 Diabetes: Chan-Hee Jung, Ae-Rin Baek, Kyu-Jin Kim, Bo-Yeon Kim, Chul-Hee Kim, Sung-Koo Kang, Ji-Oh Mok; Endocrinol Metab. 2013;28(4):309-319. Published online December 12, 2013; DOI: https://doi.org/10.3803/EnM.2013.28.4.309

5,590 View
42 Download
22 Crossref

Abstract PDF PubReader

Background

It is not clear whether microangiopathies are associated with subclinical atherosclerosis in type 2 diabetes mellitus (T2DM). We investigated the relation of cardiac autonomic neuropathy (CAN) and other microangiopathies with carotid atherosclerosis in T2DM.

Methods

A total of 131 patients with T2DM were stratified by mean carotid intima-media thickness (CIMT) ≥ or <1.0 mm and the number of carotid plaques. CAN was assessed by the five standard cardiovascular reflex tests according to the Ewing's protocol. CAN was defined as the presence of at least two abnormal tests or an autonomic neuropathy points ≥2. Diabetic microangiopathies were assessed.

Results

Patients with CAN comprised 77% of the group with mean CIMT ≥1.0 mm, while they were 29% of the group with CIMT <1.0 mm (P=0.016). Patients with diabetic retinopathy (DR) comprised 68% of the group with CIMT ≥1.0 mm, while they were 28% of the group without CIMT thickening (P=0.003). Patients with CAN comprised 51% of the group with ≥2 carotid plaques, while they were 23% of the group with ≤1 carotid plaque (P=0.014). In multivariable adjusted logistic regression analysis, the patients who presented with CAN showed an odds ratio [OR] of 8.6 (95% confidence interval [CI], 1.6 to 44.8) for CIMT thickening and an OR of 2.9 (95% CI, 1.1 to 7.5) for carotid plaques. Furthermore, patients with DR were 3.8 times (95% CI, 1.4 to 10.2) more likely to have CIMT thickening.

Conclusion

These results suggest that CAN is associated with carotid atherosclerosis, represented as CIMT and plaques, independent of the traditional cardiovascular risk factors in T2DM. CAN or DR may be a determinant of subclinical atherosclerosis in T2DM.

Citations

Citations to this article as recorded by

Common carotid artery intima media thickness (CIMT) in patients with prediabetes and newly diagnosed type 2 diabetes mellitus
Antoaneta Gateva, Yavor Assyov, Vera Karamfilova, Zdravko Kamenov
Journal of Diabetes and its Complications.2024; 38(7): 108766. CrossRef
Carotid atherosclerosis: An independent risk factor for small fiber nerve dysfunction in patients with type 2 diabetes mellitus
Simin Guo, Yali Jing, Chenxi Li, Dalong Zhu, Weimin Wang
Journal of Diabetes Investigation.2023; 14(2): 289. CrossRef
Evaluating Diagnostic Ultrasound of the Vagus Nerve as a Surrogate Marker for Autonomic Neuropathy in Diabetic Patients
Bianka Heiling, Adriana Karl, Nadin Fedtke, Nicolle Müller, Christof Kloos, Alexander Grimm, Hubertus Axer
Medicina.2023; 59(3): 525. CrossRef
Albuminuria but not low eGFR is closely associated with atherosclerosis in patients with type 2 diabetes: an observational study
Jun-Wei Wang, Jiang-Feng Ke, Zhi-Hui Zhang, Jun-Xi Lu, Lian-Xi Li
Diabetology & Metabolic Syndrome.2022;[Epub] CrossRef
Predictive Value of the Advanced Lipoprotein Profile and Glycated Proteins on Diabetic Retinopathy
Josep Julve, Joana Rossell, Eudald Correig, Marina Idalia Rojo-Lopez, Nuria Amigó, Marta Hernández, Alicia Traveset, Marc Carbonell, Nuria Alonso, Didac Mauricio, Esmeralda Castelblanco
Nutrients.2022; 14(19): 3932. CrossRef
The relationship between carotid disease and retinopathy in diabetes: a systematic review
Jocelyn J. Drinkwater, Timothy M. E. Davis, Wendy A. Davis
Cardiovascular Diabetology.2020;[Epub] CrossRef
Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II
Jocelyn J. Drinkwater, Fred K. Chen, Alison M. Brooks, Brad T. Davis, Angus W. Turner, Timothy M.E. Davis, Wendy A. Davis
Diabetes Care.2020; 43(12): 3034. CrossRef
Diabetic foot – invalidating complication of diabetes mellitus
Oana Manuela Spălăţelu, Sergiu Chirila, Leonard Gurgas, Vasile Sârbu
Medic.ro.2019; 3(129): 40. CrossRef
Clinical factors associated with the recovery of cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus
Ji Eun Jun, Seung-Eun Lee, Min Sun Choi, Sung Woon Park, You-Cheol Hwang, Jae Hyeon Kim
Cardiovascular Diabetology.2019;[Epub] CrossRef
Association of carotid intima-media thickness with exercise tolerance test in type 2 diabetic patients
Ali Momeni, Abdolmajid Taheri, Maryam Mansuri, Ali Bazdar, Morteza Sedehi, Masoud Amiri
IJC Heart & Vasculature.2018; 21: 74. CrossRef
Cardiac autonomic neuropathy may play a role in pathogenesis of atherosclerosis in type 1 diabetes mellitus
Sarka Mala, Veronika Potockova, Lucie Hoskovcova, Pavlina Pithova, Marek Brabec, Jaroslava Kulhankova, Radan Keil, Lucie Riedlbauchova, Jan Broz
Diabetes Research and Clinical Practice.2017; 134: 139. CrossRef
Cardio-Ankle Vascular Index and Indices of Diabetic Polyneuropathy in Patients with Type 2 Diabetes
Akihiko Ando, Michiaki Miyamoto, Kazuhiko Kotani, Kenta Okada, Shoichiro Nagasaka, Shun Ishibashi
Journal of Diabetes Research.2017; 2017: 1. CrossRef
Cardiac Involvement in Peripheral Neuropathies
Ahmet Z. Burakgazi, Soufian AlMahameed
Journal of Clinical Neuromuscular Disease.2016; 17(3): 120. CrossRef
The relationship between vitamin D status and cardiac autonomic neuropathy in patients with type 2 diabetes mellitus
Chan-Hee Jung, Sang-Hee Jung, Kyu-Jin Kim, Bo-Yeon Kim, Chul-Hee Kim, Sung-Koo Kang, Ji-Oh Mok
Diabetes and Vascular Disease Research.2015; 12(5): 342. CrossRef
Atorvastatin Treatment for Carotid Intima-Media Thickness in Chinese Patients With Type 2 Diabetes
Na Fang, Wei Han, Dandan Gong, Zou Chen, Yu Fan
Medicine.2015; 94(44): e1920. CrossRef
Cardiovascular complications in patients with autonomic failure
Valeria Milazzo, Cristina Di Stefano, Alberto Milan, Agnese Ravera, Gabriele Sobrero, Luca Sabia, Franco Veglio, Simona Maule
Clinical Autonomic Research.2015; 25(3): 133. CrossRef
Association of heart rate with albuminuria in a general adult population: the 2011 Korea National Health and Nutrition Examination Survey
H. S. Choi, J. W. Hong, J. H. Lee, J. H. Noh, D. J. Kim
Internal Medicine Journal.2015; 45(4): 428. CrossRef
Type 2 diabetes-associated carotid plaque burden is increased in patients with retinopathy compared to those without retinopathy
Núria Alonso, Alicia Traveset, Esther Rubinat, Emilio Ortega, Nuria Alcubierre, Jordi Sanahuja, Marta Hernández, Angels Betriu, Carmen Jurjo, Elvira Fernández, Didac Mauricio
Cardiovascular Diabetology.2015;[Epub] CrossRef
Letter: Association between Cardiac Autonomic Neuropathy, Diabetic Retinopathy and Carotid Atherosclerosis in Patients with Type 2 Diabetes (Endocrinol Metab 2013;28:309-19, Chan-Hee Jung et al.)
Hyun-Kyung Chung
Endocrinology and Metabolism.2014; 29(1): 101. CrossRef
Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251. CrossRef
Clinical utility of serum beta-2-microglobulin as a predictor of diabetic complications in patients with type 2 diabetes without renal impairment
M.K. Kim, K.-J. Yun, H.J. Chun, E.-H. Jang, K.-D. Han, Y.-M. Park, K.-H. Baek, K.-H. Song, B.-Y. Cha, C.S. Park, H.-S. Kwon
Diabetes & Metabolism.2014; 40(6): 459. CrossRef
Association between Brachial-Ankle pulse wave velocity and cardiac autonomic neuropathy in type 2 diabetes
Nan Wu, Xiaoling Cai, Kuanping Ye, Yintao Li, Min He, Weiwei Zhao, Renming Hu
Diabetology & Metabolic Syndrome.2014;[Epub] CrossRef

Author index